Altimmune Stock Performance
| ALT Stock | USD 4.87 0.05 1.02% |
On a scale of 0 to 100, Altimmune holds a performance score of 5. The firm shows a Beta (market volatility) of 0.66, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Altimmune's returns are expected to increase less than the market. However, during the bear market, the loss of holding Altimmune is expected to be smaller as well. Please check Altimmune's value at risk, as well as the relationship between the skewness and day median price , to make a quick decision on whether Altimmune's price patterns will revert.
Risk-Adjusted Performance
Mild
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Altimmune are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively uncertain essential indicators, Altimmune unveiled solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (1.02) | Five Day Return (3.56) | Year To Date Return 38.75 | Ten Year Return (96.34) | All Time Return (96.34) |
Last Split Factor 1:30 | Dividend Date 2018-09-14 | Ex Dividend Date 2017-01-20 | Last Split Date 2018-09-14 |
1 | Acquisition by Vipin Garg of 18950 shares of Altimmune subject to Rule 16b-3 | 11/21/2025 |
2 | Disposition of 7231 shares by Vipin Garg of Altimmune at 6.64 subject to Rule 16b-3 | 12/05/2025 |
3 | Disposition of 11701 shares by Vipin Garg of Altimmune at 7.0 subject to Rule 16b-3 | 12/12/2025 |
4 | Disposition of 9375 shares by Jordt Raymond M of Altimmune subject to Rule 16b-3 | 12/31/2025 |
5 | Offsite Data Center Power Infrastructure Market Projected to Reach US 79.76 Billion by 2035, Supported by Long-Term Power Procurement Strategies Says Astute Ana... | 01/07/2026 |
6 | LNG Bunkering Market to Worth Over US 202.13 Billion by 2033 Astute Analytica | 01/12/2026 |
7 | Electric Wheelchair Market Poised to Grow to US 19.12 Billion by 2033 Astute Analytica | 01/13/2026 |
8 | Acquisition by Vipin Garg of 26775 shares of Altimmune subject to Rule 16b-3 | 01/26/2026 |
9 | Disposition of 15850 shares by Roberts M Scot of Altimmune subject to Rule 16b-3 | 01/27/2026 |
10 | Altimmune prices 75M direct offering | 01/28/2026 |
11 | Disposition of 26775 shares by Vipin Garg of Altimmune subject to Rule 16b-3 | 01/30/2026 |
12 | Altimmune, Inc. Gains Analyst Support Ahead of Phase 3 MASH Development | 02/02/2026 |
13 | Acquisition by Lawver Teri L of 69800 shares of Altimmune at 6.11 subject to Rule 16b-3 | 02/03/2026 |
| Begin Period Cash Flow | 135.2 M | |
| Total Cashflows From Investing Activities | -28.4 M |
Altimmune | Build AI portfolio with Altimmune Stock |
Altimmune Relative Risk vs. Return Landscape
If you would invest 426.00 in Altimmune on November 9, 2025 and sell it today you would earn a total of 61.00 from holding Altimmune or generate 14.32% return on investment over 90 days. Altimmune is generating 0.4138% of daily returns assuming volatility of 6.2042% on return distribution over 90 days investment horizon. In other words, 55% of stocks are less volatile than Altimmune, and above 92% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
Altimmune Target Price Odds to finish over Current Price
The tendency of Altimmune Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 4.87 | 90 days | 4.87 | about 35.81 |
Based on a normal probability distribution, the odds of Altimmune to move above the current price in 90 days from now is about 35.81 (This Altimmune probability density function shows the probability of Altimmune Stock to fall within a particular range of prices over 90 days) .
Altimmune Price Density |
| Price |
Predictive Modules for Altimmune
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Altimmune. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Altimmune Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Altimmune is not an exception. The market had few large corrections towards the Altimmune's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Altimmune, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Altimmune within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.44 | |
β | Beta against Dow Jones | 0.66 | |
σ | Overall volatility | 0.66 | |
Ir | Information ratio | 0.07 |
Altimmune Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Altimmune for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Altimmune can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Altimmune had very high historical volatility over the last 90 days | |
| The company reported the last year's revenue of 20 K. Reported Net Loss for the year was (95.06 M) with loss before taxes, overhead, and interest of (67.78 M). | |
| Altimmune has about 184.76 M in cash with (79.85 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.81. | |
| Altimmune has a frail financial position based on the latest SEC disclosures | |
| Latest headline from finance.yahoo.com: Altimmune, Inc. Gains Analyst Support Ahead of Phase 3 MASH Development |
Altimmune Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Altimmune Stock often depends not only on the future outlook of the current and potential Altimmune's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Altimmune's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 71 M | |
| Cash And Short Term Investments | 131.9 M |
Altimmune Fundamentals Growth
Altimmune Stock prices reflect investors' perceptions of the future prospects and financial health of Altimmune, and Altimmune fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Altimmune Stock performance.
| Return On Equity | -0.53 | ||||
| Return On Asset | -0.31 | ||||
| Current Valuation | 420.02 M | ||||
| Shares Outstanding | 125.23 M | ||||
| Price To Earning | (1.66) X | ||||
| Price To Book | 3.31 X | ||||
| Price To Sales | 30,807 X | ||||
| Revenue | 20 K | ||||
| Gross Profit | (67.78 M) | ||||
| EBITDA | (94.81 M) | ||||
| Net Income | (95.06 M) | ||||
| Cash And Equivalents | 184.76 M | ||||
| Cash Per Share | 3.81 X | ||||
| Total Debt | 1.68 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 14.12 X | ||||
| Book Value Per Share | 1.94 X | ||||
| Cash Flow From Operations | (79.85 M) | ||||
| Earnings Per Share | (1.07) X | ||||
| Market Capitalization | 616.14 M | ||||
| Total Asset | 139.31 M | ||||
| Retained Earnings | (561.39 M) | ||||
| Working Capital | 126.79 M | ||||
| Current Asset | 13.9 M | ||||
| Current Liabilities | 10.49 M | ||||
About Altimmune Performance
Assessing Altimmune's fundamental ratios provides investors with valuable insights into Altimmune's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Altimmune is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 63.07 | 56.06 | |
| Return On Tangible Assets | (0.78) | (0.82) | |
| Return On Capital Employed | (0.72) | (0.76) | |
| Return On Assets | (0.78) | (0.82) | |
| Return On Equity | (0.69) | (0.73) |
Things to note about Altimmune performance evaluation
Checking the ongoing alerts about Altimmune for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Altimmune help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Altimmune had very high historical volatility over the last 90 days | |
| The company reported the last year's revenue of 20 K. Reported Net Loss for the year was (95.06 M) with loss before taxes, overhead, and interest of (67.78 M). | |
| Altimmune has about 184.76 M in cash with (79.85 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.81. | |
| Altimmune has a frail financial position based on the latest SEC disclosures | |
| Latest headline from finance.yahoo.com: Altimmune, Inc. Gains Analyst Support Ahead of Phase 3 MASH Development |
- Analyzing Altimmune's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Altimmune's stock is overvalued or undervalued compared to its peers.
- Examining Altimmune's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Altimmune's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Altimmune's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Altimmune's stock. These opinions can provide insight into Altimmune's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Altimmune Stock Analysis
When running Altimmune's price analysis, check to measure Altimmune's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Altimmune is operating at the current time. Most of Altimmune's value examination focuses on studying past and present price action to predict the probability of Altimmune's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Altimmune's price. Additionally, you may evaluate how the addition of Altimmune to your portfolios can decrease your overall portfolio volatility.